Evidence map›Paper›PMID 35778828›Full record

ReviewAdvanced biology2022

Bioengineering Extracellular Vesicles for the Treatment of Cardiovascular Diseases.

Lalithasri Ramasubramanian, Shixian Du, Siraj Gidda, Nataliya Bahatyrevich, Dake Hao, Priyadarsini Kumar, Aijun Wang

Open access · greenAbstract readReview
In one paragraph

Review in Advanced biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lalithasri RamasubramanianDepartment of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA.
Shixian DuDepartment of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA.
Siraj GiddaDepartment of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA.
Nataliya BahatyrevichDepartment of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA.
Dake HaoDepartment of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA.
Priyadarsini KumarDepartment of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA.
Aijun WangDepartment of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA.ORCID 0000-0002-2985-3627
Shriners Hospitals for Children - Erie · USUniversity of California, Davis · US

Funding

Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
NHLBI NIH HHS T32 HL086350
6 · The paper itself

Abstract

Cardiovascular diseases (CVD) remain one of the leading causes of mortality worldwide. Despite recent advances in diagnosis and interventions, there is still a crucial need for new multifaceted therapeutics that can address the complicated pathophysiological mechanisms driving CVD. Extracellular vesicles (EVs) are nanovesicles that are secreted by all types of cells to transport molecular cargo and regulate intracellular communication. EVs represent a growing field of nanotheranostics that can be leveraged as diagnostic biomarkers for the early detection of CVD and as targeted drug delivery vesicles to promote cardiovascular repair and recovery. Though a promising tool for CVD therapy, the clinical application of EVs is limited by the inherent challenges in EV isolation, standardization, and delivery. Hence, this review will present the therapeutic potential of EVs and introduce bioengineering strategies that augment their natural functions in CVD.

Indexed as

Cardiovascular DiseasesExtracellular VesiclesBioengineeringBiomarkersDrug Delivery SystemsHumansBiomarkerscardiovascular diseasecargo loadingextracellular vesiclesnanotherapeuticstargeted delivery

Identifiers

PMID35778828
PMCPMC9588622
OpenAlexW4283777330

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.